J. Shapiro

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus

Robert F Coniff, J. Shapiro, Timothy B. Seaton et al. · The American Journal of Medicine · 1995 · 181 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +10

A Double-Blind Placebo-Controlled Trial Evaluating the Safety and Efficacy of Acarbose for the Treatment of Patients With Insulin-Requiring Type II Diabetes

Robert F Coniff, J. Shapiro, Timothy B. Seaton et al. · Diabetes Care · 1995 · 91 citations

140O Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC)

Eric Van Cutsem, Fortunato Ciardiello, Jean‐François Seitz et al. · Annals of Oncology · 2015 · 20 citations · Full text

Open-label Phase 3B, Gastrointestinal Oncology, Medicine +9

2139 CONSIGN: An open-label phase 3B study of regorafenib in patients with metastatic colorectal cancer (mCRC) who failed standard therapy

Eric Van Cutsem, Fortunato Ciardiello, J.F. Seitz et al. · European Journal of Cancer · 2015 · 11 citations

Open-label Phase 3B, Gastrointestinal Oncology, Medicine +9